Results 1 to 10 of about 538,734 (195)

Optical Coherence Tomography to Assess Neurodegeneration in Phenylalanine Hydroxylase Deficiency [PDF]

open access: yesFrontiers in Neurology, 2021
In phenylalanine hydroxylase (PAH) deficiency, an easily feasible method to access the progression of neurodegeneration is warranted to contribute to current discussions on treatment indications and targets.
Amelie S. Lotz-Havla   +9 more
doaj   +10 more sources

Genotypes of patients with phenylalanine hydroxylase deficiency in the Wisconsin Amish [PDF]

open access: yesMolecular Genetics and Metabolism Reports, 2018
In the Plain Community, there is an increased frequency of genetic disorders including phenylalanine hydroxylase (PAH) deficiency. Common pathogenic variants have been observed due to founder effect and closed community.
Jessica Scott Schwoerer   +4 more
doaj   +5 more sources

Concurrent Phenylalanine Hydroxylase–Related Disorder and Celiac: A Rare Co-occurrence With Implications for Clinical Management [PDF]

open access: yesAnnals of Internal Medicine: Clinical Cases
Comorbid nutritional disorders can present with clinical management challenges. Phenylalanine hydroxylase (PAH) deficiency and celiac disease are both associated with dietary protein intolerance, yet they are different disorders.
Jade Jensen   +6 more
doaj   +4 more sources

Strategies for Successful Long-Term Engagement of Adults With Phenylalanine Hydroxylase Deficiency Returning to the Clinic

open access: yesJournal of Inborn Errors of Metabolism and Screening, 2017
Nearly half of all patients diagnosed with phenylalanine hydroxylase (PAH) deficiency, also known as phenylketonuria, are lost to follow-up (LTFU); most are adults who stopped attending clinic after the age of 18 years.
Janet Thomas MD   +5 more
doaj   +4 more sources

Phenylalanine Hydroxylase Deficiency and Citrin Deficiency in a Chinese Infant [PDF]

open access: yesChinese Medical Journal, 2015
To the Editor: Tandem mass spectrometry (MS/MS)-based expanded newborn screening was first introduced in Pediatric Endocrinology/Genetics of Xin Hua Hospital in 2003. The screening is expected to detect genetic disorders leading to a secondary increase in blood phenylalanine (Phe) in newborns.[1] We reported a rare case in a Chinese infant with ...
Jun Ye   +4 more
doaj   +3 more sources

Screening and mutation analysis of phenylalanine hydroxylase deficiency in newborns from Jiangxi province [PDF]

open access: yesFrontiers in Genetics, 2023
Background: Phenylalanine hydroxylase deficiency (PAHD) is an autosomal recessive disorder of amino acid metabolism and caused by mutations in the phenylalanine hydroxylase (PAH) gene. Without timely and appropriate dietary management, the disturbance of
Baitao Zeng   +18 more
doaj   +2 more sources

Birth prevalence of phenylalanine hydroxylase deficiency: a systematic literature review and meta-analysis [PDF]

open access: yesOrphanet Journal of Rare Diseases, 2021
Background Phenylalanine hydroxylase (PAH) deficiency is an autosomal recessive disorder that results in elevated concentrations of phenylalanine (Phe) in the blood.
Pamela K. Foreman   +7 more
doaj   +2 more sources

Metabolic Control and Frequency of Clinical Monitoring Among Canadian Children With Phenylalanine Hydroxylase Deficiency: A Retrospective Cohort Study [PDF]

open access: yesJIMD Reports
Achieving and maintaining metabolic control is critical for children with phenylalanine hydroxylase (PAH) deficiency. This retrospective longitudinal cohort study investigated metabolic control and monitoring frequency of children with PAH deficiency ...
Nataliya Yuskiv   +28 more
doaj   +2 more sources

Maximal dietary responsiveness after tetrahydrobiopterin (BH4) in 19 phenylalanine hydroxylase deficiency patients: What super-responders can expect [PDF]

open access: yesMolecular Genetics and Metabolism Reports
Background: Inherited phenylalanine hydroxylase deficiency, also known as phenylketonuria (PKU), causes poor growth and neurologic deficits in the untreated state.
Jariya Upadia   +8 more
doaj   +2 more sources

Phenylalanine–tyrosine–catecholamine axis disorders: pathways, molecular diagnosis, therapeutics, and emerging translational monitoring technologies [PDF]

open access: yesFrontiers in Molecular Biosciences
Disorders of the phenylalanine–tyrosine–catecholamine axis are a clinically relevant group of neurometabolic conditions in which pathogenic variants in key enzymes impair dopamine and norepinephrine biosynthesis.
Martina Isabella Armas Samaniego   +12 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy